PRLD Prelude Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRLD

Price (delayed)

$4.075

Market cap

$324.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$317.28M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 37

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective ...

Highlights
PRLD's gross profit has surged by 139% year-on-year and by 38% since the previous quarter
The revenue has soared by 139% year-on-year and by 38% since the previous quarter
The quick ratio has plunged by 61% YoY
The equity has declined by 42% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://preludetx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PRLD

PRLD stock price

How has the Prelude Therapeutics stock price performed over time
Intraday
11.34%
1 week
3.69%
1 month
-14.03%
1 year
307.54%
YTD
40.52%
QTD
19.15%

Financial performance

How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$16.72M
Gross profit
$16.72M
Operating income
-$84.14M
Net income
-$77.8M
Gross margin
100%
Net margin
-465.3%
PRLD's gross profit has surged by 139% year-on-year and by 38% since the previous quarter
The revenue has soared by 139% year-on-year and by 38% since the previous quarter
The net margin has soared by 75% YoY and by 43% QoQ
PRLD's operating margin has soared by 75% YoY and by 42% from the previous quarter

Price vs fundamentals

How does PRLD's price correlate with its fundamentals

Growth

What is Prelude Therapeutics's growth rate over time

Valuation

What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
4.27
P/S
20.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.98
The EPS has increased by 41% year-on-year and by 22% since the previous quarter
The stock's P/B is 139% above its 5-year quarterly average of 1.6 and 82% above its last 4 quarters average of 2.1
The equity has declined by 42% year-on-year and by 12% since the previous quarter
The revenue has soared by 139% year-on-year and by 38% since the previous quarter
The stock's price to sales (P/S) is 33% more than its last 4 quarters average of 13.6

Efficiency

How efficient is Prelude Therapeutics business performance
The return on sales has surged by 75% year-on-year and by 43% since the previous quarter
Prelude Therapeutics's ROIC has decreased by 41% YoY but it has increased by 15% from the previous quarter
PRLD's return on equity is down by 33% year-on-year but it is up by 9% since the previous quarter
The ROA has grown by 18% from the previous quarter and by 4.6% YoY

Dividends

What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRLD.

Financial health

How did Prelude Therapeutics financials performed over time
The total assets is 101% greater than the total liabilities
The current ratio has dropped by 61% year-on-year but it is up by 2% since the previous quarter
The quick ratio has plunged by 61% YoY
The debt is 71% lower than the equity
PRLD's debt to equity has surged by 71% year-on-year and by 12% since the previous quarter
The equity has declined by 42% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.